WO1998001157A1 - Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter - Google Patents
Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter Download PDFInfo
- Publication number
- WO1998001157A1 WO1998001157A1 PCT/GB1997/001822 GB9701822W WO9801157A1 WO 1998001157 A1 WO1998001157 A1 WO 1998001157A1 GB 9701822 W GB9701822 W GB 9701822W WO 9801157 A1 WO9801157 A1 WO 9801157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neuropathy
- vitamin
- neurotransmitter
- treatment
- components
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Definitions
- the present invention relates to the use of a combined medicament in the treatment of various forms of peripheral neuropathy, especially painful neuropathies and diabetic neuropathy, including diabetic amyotrophy, mononeuritis, mononeuritis multiplex, cranial nerve palsies and autonomic neuropathy.
- the invention also relates to the preparation of medicaments for such treatments .
- Diabetes melli tus is a metabolic disorder resulting in hyperglycaemia (raised blood sugar) , polyuria
- glycosuria increasing output of urine
- sugars e.g. glucose
- Diabetes has been recognised as a major disease for centuries. In addition to defective carbohydrate metabolism, it can also lead to altered metabolism of lipids and proteins and patients are at risk of complications from microvascular and macrovascular diseases which are serious and may be fatal.
- Insulin dependent diabetes results from failure of the islets of Langerhans ( ⁇ ) cells of the pancreas to produce sufficient insulin. This often arises as a result of auto- immunity directed against islet tissue.
- Non- insulin-dependent diabetes may in part arise from altered efficiency of insulin receptor signalling (insulin resistance) or from a relative deficiency of insulin.
- Insulin resistance insulin receptor signalling
- Detectable diabetic neuropathy occurs in approximately 60% of diabetic patients. Some 20% of diabetic patients show moderate to severe symptoms, the severity is generally thought to be linked to the duration of diabetic symptoms and the level of control using e.g. insulin, or oral hypoglycaemic agents such as the sulphonylureas .
- Diabetic neuropathy may be mild, for example taking the form of "burning" or tingling in the feet or numbness and/or loss of vibration sense in the extremities, especially the feet. Moderate to severe symptoms of neuropathy include pain and spasm in the extremities (painful neuropathy with spasm) . Diabetic amyotrophy is indicated by pain over the thigh and loss of quadriceps power, sometimes also loss of power in the lower leg resulting in foot drop. Autonomic neuropathy principally affects the nerves supplying the heart and viscera. Mononeuritis is usually caused by a single peripheral nerve palsy. Other peripheral neuropathies include the following:
- HIV associated neuropathy B 12 -deficiency associated neuropathy; cranial nerve palsies; drug- induced neuropathy; - industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi- focal motor neuropathy; chronic ldiopathic sensory neuropathy; carcmomatous neuropathy; acute pan autonomic neuropathy; alcoholic neuropathy; - compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and poly- neuropathies.
- Type I diabetes insulin dependent diabetes
- type II diabetes non-insulin dependent diabetes
- neuropathy Both type I (insulin dependent) diabetes and type II (non-insulin dependent) diabetes are associated with neuropathy.
- Type I diabetes commonly presents in relatively young adults, often with diabetic ketoacidosis, type II diabetes (also know as maturity onset diabetes) often occurs in middle age or in elderly patients.
- Type II diabetes is particularly associated with the relatively late and severe onset of neuropathy.
- gamolenic acid may reduce symptoms, and prevent the progression of abnormalities in nerve conduction studies in diabetic neuropathy.
- WO 96/11009 discloses treatment of multiple sclerosis by some of the combinations of components employed in the present invention.
- Vitamin B 12 has been proposed for the treatment of B 12 -deficiency associated neuropathy.
- the present inventor has surprisingly found that a combination of an antidepressant or a monamine oxidase inhibitor (MAOI) with an inducer or a precursor of a neurotransmitter can be effective in the treatment of peripheral neuropathies, and in particular painful neuropathy.
- the components of this medicament may be presented as a combined preparation for simultaneous, separate or sequential use in the treatment of various peripheral neuropathies. It has also been oDserved that a parallel or simultaneous administration of vitamin B 12 treatment, for example orally or by injection, may enhance the therapeutic effect of this combination.
- the present invention provides the use of any one of the following components or combinations of components : C,
- A is an antidepressant or a monoamine oxidase inhibiter
- B is vitamin B 12
- C is a precursor or inducer of a neurotransmitter, in the manufacture of a medicament for the treatment of at least one form of peripheral neuropathy.
- the invention provides a method of making a medicament for the treatment of a patient suffering from a peripheral neuropathy, comprising admixing any one of the following components: C,
- A is an antidepressant or a monoamine oxidase inhibiter
- B is vitamin B 12 .
- C is a precursor or inducer of a neurotransmitter, with at least one pharmaceutically acceptable component or vehicle to prepare a medicament suitable for administration to a patient.
- the invention provides a method of treatment of a patient suffering from a form of peripheral neuropathy, comprising administering to the patient any one of the following combinations of components :
- a s an antidepressant or a monoamine oxidase inhibitor, B is vitamin B 12 , and
- C is a precursor or inducer of a neurotransmitter , said components being administered simultaneously or separately, m amounts which m combination have the effect of ameliorating the peripheral neuropathy.
- the invention provides a pharmaceutical composition containing as the only pharmaceutically active components vitamin B 12 and a precursor or inducer of a neurotransmitter. Treatment may be simultaneous or separate including sequential administration of the components
- At least one pharmaceutically acceptable component or vehicle such as an incipient, carrier, buffer, stabiliser or other material, as. discussed below.
- kits or pack containing components A and B, or A and C, or A and B and C, or B and C, wherein component A the components being formulated for simultaneous, separate or sequential delivery in the treatment of peripheral neuropathy.
- Particularly components A and C may be combined, and component B separate .
- the diabetic neuropathy with which the present invention is concerned may be characterised by degeneration of the long nerves (the nerves of the peripheral nervous system) as a result of the metabolic disturbances of diabetes. This can be contrasted with other neurodegenerative disorders such multiple sclerosis, the effects of which are concentrated in the central nervous system.
- the present invention is applicable to any and all of peripheral neuropathies, particularly painful neuropathies, including those listed above in the introduction.
- Preferred antidepressants for use in the present invention include tricyclic and tetracyclic antidepressants such as lofepramine and selected seritonin re-uptake inhibitors (SSRI) . Lofepramine and certain other tricyclic antidepressants also show some monoamine oxidase inhibitor (MAOI) activity.
- tricyclic and tetracyclic antidepressants such as lofepramine and selected seritonin re-uptake inhibitors (SSRI) .
- Lofepramine and certain other tricyclic antidepressants also show some monoamine oxidase inhibitor (MAOI) activity.
- Suitable antidepressants and MAOIs include ianserin, trimipramine, imipramine, clomipramine , amitriptyline, protriptyline, nortriptyline, fluvoxamine, fluoxetine, maprotiline, sertaline, venlaflaxine , pargyline, triazolopyridine, phenelzine, tranylcypromine, desipramine, moclopemide, dothiepin, doxepin, paroxetine, oxazine or viloxazine, amongst others.
- a neurotransmitter inducer is a component which enhances or triggers production of a neurotransmitter.
- a preferred neurotransmitter precursor for use in the present invention is L-phenylalanine (LPA) .
- L-tryptophan may also find use in the present invention.
- Other amino acids such as L-tyrosine or other compounds such as tyra ine may also find use in the present invention as a neurotransmitter, inducer or precursor.
- Compounds may be provided as a metabolite of a precursor.
- L-phenylalanine may be provided as a metabolite of aspartame.
- the combination for treatment includes vitamin B 12 , this may be in the form of cyanocobalamin or hydroxycobalamin, to be administered orally or intramuscularly .
- compositions provided herein may comprise an antidepressant or a monoamine oxidase inhibitor (MAOI) and a neurotransmitter precursor or inducer, or any other combination of components disclosed herein, as combined (simultaneous or sequential) actives.
- MAOI monoamine oxidase inhibitor
- compounds may be employed which mimic a given active in improving diagnostic status and/or ameliorating one or more symptoms of diabetic neuropathy (mimetics) .
- Such compounds and their use are within the scope of the present invention.
- derivatives or analogues of the antidepressant or MAOI which retain the antidepressant or MAOI activity, respectively.
- compositions provided may be administered to individuals. Administration is preferably in a "therapeutically effective amount", this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, eg decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors. Dose regimens for the MAOIs and antidepressants may be within the range used for the treatment of depression (for which the standard starting dose of lofepramine is 140mg per day) .
- a possible range for administration of antidepressants is 10-210mg per day, although 50-70mg per day may be suitable.
- a range of lOOmg to 5g per day, preferably 500-2000mg/d (mg per day) may be employed, the dose increasing in proportion to the level of antidepressant or MAOI employed.
- a 70mg dose of lofepramine may be combined with 500mg of L-phenylalanine given in the morning, this being supplemented with a further 500mg of L-phenylalanine given in the afternoon.
- vitamin B 12 is co-administered
- the amounts may be those generally recommended for daily intake of the vitamin or may be greater than that recommended as average daily intake.
- the preferred average dosage range for vitamin B 12 in the invention is from lmg every 3 months up to lmg every 3 days. When symptoms are severe, this may be lmg intramuscular hydroxycobalamin per week in an 8-10 week course at the start of treatment, perhaps reduced to lmg every 10 days as treatment progresses.
- the desired dosage level of vitamin B 12 may conveniently be given by weekly intramuscular injection, but doses ranging from 5 ⁇ g to lOmg may be given daily orally.
- compositions according to the present invention may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous .
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may comprise a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- L-tryptophan and L-phenylalanine are available in 500mg tablets.
- a combined oral preparation in single tablet form containing all these components A, B and C, or for example components B and C, is feasible.
- a treatment pack may contain the components separately.
- Case #3 This case studied here is of the same 48 year old male with diabetic neuropathy as in case #1, but after the original observation in case #1. The patient was subsequently continued on the same vitamin B 12 injections and phenylalanine (500mg twice daily) only. He continued to benefit from his therapy whilst on these two drugs only, for approximately two months, and then required the recommencement of lofepramine to maintain good effect clinically.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34517/97A AU3451797A (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
US09/214,314 US6335323B2 (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter |
DE69715899T DE69715899T2 (en) | 1996-07-05 | 1997-07-04 | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHY, CONTAINING THE ANTIDEPRESSIVE COMPOUNDS AND / OR MONOAMINO-OXIDAS INHIBITORS AND / OR VITAMIN B12 AND / OR NEURO TRANSMITTER PRECURSORS OR INDUCTORS |
AT97930634T ATE224733T1 (en) | 1996-07-05 | 1997-07-04 | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHY CONTAINING ANTIDEPRESSANT COMPOUNDS AND/OR MONOAMINO-OXIDASINE INHIBITORS AND/OR VITAMIN B12 AND/OR NEUROTRANSMITTER PRECURSORS OR INDUCTORS |
EP97930634A EP0942751B1 (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
DK97930634T DK0942751T3 (en) | 1996-07-05 | 1997-07-04 | Preparations for the treatment of peripheral neuropathies containing antidepressants and / or monoamine oxidase inhibitors and / or vitamin B12 and / or precursor to or induce a neurotransmitter |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9614121.3A GB9614121D0 (en) | 1996-07-05 | 1996-07-05 | Combined medicament |
GB9614121.3 | 1996-07-05 | ||
GB9616019.7 | 1996-07-31 | ||
GBGB9616019.7A GB9616019D0 (en) | 1996-07-05 | 1996-07-31 | Combined medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998001157A1 true WO1998001157A1 (en) | 1998-01-15 |
Family
ID=26309637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/001822 WO1998001157A1 (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
Country Status (10)
Country | Link |
---|---|
US (1) | US6335323B2 (en) |
EP (1) | EP0942751B1 (en) |
AT (1) | ATE224733T1 (en) |
AU (1) | AU3451797A (en) |
CA (1) | CA2259010A1 (en) |
DE (1) | DE69715899T2 (en) |
DK (1) | DK0942751T3 (en) |
ES (1) | ES2184111T3 (en) |
PT (1) | PT942751E (en) |
WO (1) | WO1998001157A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059598A1 (en) * | 1998-05-19 | 1999-11-25 | Dalhousie University | Use of tricyclic antidepressants for local analgesia |
WO2000050028A1 (en) * | 1999-02-24 | 2000-08-31 | Andrew Peter Worsley | Compositions for the treatment of pain |
WO2000056404A1 (en) * | 1999-03-24 | 2000-09-28 | Kilgowan Limited | Formulations for treatment of pain comprising vitamin b12 and phenylanine |
US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US6451788B1 (en) | 1996-08-29 | 2002-09-17 | The Wwk Trust Of 225-235 High Street | Treatment of pain |
WO2007088473A2 (en) * | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
GB2544630A (en) * | 2015-11-19 | 2017-05-24 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
US6759437B2 (en) | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
EP1603448A4 (en) * | 2003-02-21 | 2007-12-05 | Martin C Hinz | Serotonin and catecholamine system segment optimization technology |
JP4638685B2 (en) * | 2003-06-10 | 2011-02-23 | ハイデルベルガー ドルツクマシーネン アクチエンゲゼルシヤフト | Method of metering dampening water during printing on an offset press |
GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011009A1 (en) * | 1994-10-05 | 1996-04-18 | Cari Loder | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3981863A (en) * | 1975-02-25 | 1976-09-21 | Micromedic Diagonistics, Inc. | Cyanocobalamin derivatives |
US4431670A (en) | 1980-12-19 | 1984-02-14 | Bernardo Heller | D-Phenylalanine treatment |
US4652559A (en) | 1982-08-16 | 1987-03-24 | The Upjohn Company | 2-(Phenylmethylene)cycloalkyl-azetidines |
-
1997
- 1997-07-04 ES ES97930634T patent/ES2184111T3/en not_active Expired - Lifetime
- 1997-07-04 DE DE69715899T patent/DE69715899T2/en not_active Expired - Fee Related
- 1997-07-04 US US09/214,314 patent/US6335323B2/en not_active Expired - Fee Related
- 1997-07-04 WO PCT/GB1997/001822 patent/WO1998001157A1/en active IP Right Grant
- 1997-07-04 AT AT97930634T patent/ATE224733T1/en not_active IP Right Cessation
- 1997-07-04 AU AU34517/97A patent/AU3451797A/en not_active Abandoned
- 1997-07-04 EP EP97930634A patent/EP0942751B1/en not_active Expired - Lifetime
- 1997-07-04 DK DK97930634T patent/DK0942751T3/en active
- 1997-07-04 PT PT97930634T patent/PT942751E/en unknown
- 1997-07-04 CA CA002259010A patent/CA2259010A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011009A1 (en) * | 1994-10-05 | 1996-04-18 | Cari Loder | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
Non-Patent Citations (3)
Title |
---|
CALANCA A.: "HYDROXYTRYPTOPHANE (OXITRIPTAN) EN ASSOCIATION AVEC LES ANTIDEPRESSEURS CLASSIQUES: UNE ULTERIEURE POSSIBILITE THERAPEUTIQUE", SCHWEIZ. RUNDSCH. MED. PRAX., 1988, 77/34 SUPPL. (47-50), SWITZERLAND, XP002047639 * |
OKADA S ET AL: "EFFECT OF METHYLCOBALAMIN ON DIMINISHED MOTOR NERVE CONDUCTION VELOCITY IN THE TIBIAL NERVE OF POORLY CONTROLLED DIABETICS", CLIN TRIALS J, 22 (6). 1985 (RECD. 1986). 534-536., XP002047637 * |
SIMON K.H.: "ZUR BEHANDLUNG THERAPIERESISTENTER SCHMERZZUSTANDE MIT HYDROXOCOBALAMIN", MED.MSCHR., 1974, 28/10 (466-468), GERMANY, WEST, XP002047638 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
US6897241B2 (en) | 1995-09-22 | 2005-05-24 | Bruce M. Frome | Preparation of topical regional compositions for the relief of pain |
US6387957B1 (en) | 1995-09-22 | 2002-05-14 | Bruce M. Frome | Preparation of topical regional compositions for the relief of pain |
US6451788B1 (en) | 1996-08-29 | 2002-09-17 | The Wwk Trust Of 225-235 High Street | Treatment of pain |
US6989380B2 (en) | 1996-08-29 | 2006-01-24 | The Wkk Trust | Treatment of pain |
WO1999059598A1 (en) * | 1998-05-19 | 1999-11-25 | Dalhousie University | Use of tricyclic antidepressants for local analgesia |
WO2000050028A1 (en) * | 1999-02-24 | 2000-08-31 | Andrew Peter Worsley | Compositions for the treatment of pain |
WO2000056404A1 (en) * | 1999-03-24 | 2000-09-28 | Kilgowan Limited | Formulations for treatment of pain comprising vitamin b12 and phenylanine |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
WO2001026623A3 (en) * | 1999-10-12 | 2001-06-21 | Laxdale Ltd | Treatment of fatigue, head injury and stroke |
WO2001026623A2 (en) * | 1999-10-12 | 2001-04-19 | Laxdale Limited | Treatment of fatigue, head injury and stroke |
US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US8809010B2 (en) | 2003-05-05 | 2014-08-19 | Probiodrug Ag | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases |
WO2007088473A2 (en) * | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
WO2007088473A3 (en) * | 2006-02-03 | 2008-02-14 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
EP2481408A2 (en) | 2007-03-01 | 2012-08-01 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
GB2544630A (en) * | 2015-11-19 | 2017-05-24 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
WO2017085437A1 (en) | 2015-11-19 | 2017-05-26 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Also Published As
Publication number | Publication date |
---|---|
DE69715899T2 (en) | 2003-05-28 |
ES2184111T3 (en) | 2003-04-01 |
PT942751E (en) | 2003-02-28 |
US6335323B2 (en) | 2002-01-01 |
EP0942751B1 (en) | 2002-09-25 |
DK0942751T3 (en) | 2002-12-02 |
EP0942751A1 (en) | 1999-09-22 |
AU3451797A (en) | 1998-02-02 |
US20010008884A1 (en) | 2001-07-19 |
DE69715899D1 (en) | 2002-10-31 |
ATE224733T1 (en) | 2002-10-15 |
CA2259010A1 (en) | 1998-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0942751B1 (en) | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter | |
ES2309351T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE DEXTROMETORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS. | |
US6294583B1 (en) | Methods of treating tardive dyskinesia and other movement disorders | |
EP0784476B1 (en) | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound | |
JP4562911B2 (en) | Method for treating tardive dyskinesia and other movement disorders | |
WO2013138322A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
CA2230690C (en) | Administration of ketamine to manage pain and to reduce drug dependency | |
AU2004311869A1 (en) | Compositions and methods to treat recurrent medical conditions | |
AU2009304002B9 (en) | A medicinal product and treatment | |
US20150250761A1 (en) | Compositions and methods for treatment of chronic fatigue | |
ES2626651T3 (en) | Compositions for the treatment of chronic fatigue | |
US20070173478A1 (en) | Compositions for the enhanced treatment of depression | |
ES2917618T3 (en) | Treatment of alcoholism and depression through the use of ibudilast | |
WO2008010768A1 (en) | Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method | |
JP2005306882A (en) | Composition useful for preparation of medicine for treating emotional instability | |
US20050196433A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
WO2000050028A1 (en) | Compositions for the treatment of pain | |
Chunder | Pregabalin | |
EP2285386B1 (en) | Use of ribose in the treatment of restless legs syndrome | |
WO2017085437A1 (en) | Combinations for the treatment of dementia, and the enhancement of cognitive function | |
JP2005255695A (en) | Composition useful for production of medicine for treating chronic pain | |
AU2013203567A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2259010 Country of ref document: CA Ref country code: CA Ref document number: 2259010 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997930634 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09214314 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98504936 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997930634 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997930634 Country of ref document: EP |